Jan. 6, 2025 /Mpelembe Media/ — , a medical technology company, is partnering with the Mayo Clinic to pilot its Nevisense device in the US. Nevisense, an FDA-approved AI-powered tool, aids in the early detection of melanoma, the deadliest form of skin cancer. Continue reading
A major study published in leading cancer journal, The Lancet Oncology1 have ground-breaking findings on Michelson Diagnostics, the UK based medical device company that use multi-beam Optical Coherence Tomography (‘OCT’) technology, which can transform patient’s treatment and care of basal cell carcinomas (BCC). It was concluded that OCT-guided diagnosis, when compared to a standard punch biopsy could reduce the number of consultations and invasive procedures by a massive 66%. Continue reading